{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:06:56Z","timestamp":1747181216142,"version":"3.40.5"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,30]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Most people diagnosed with chronic hepatitis B (CHB) need treatment to help reduce the risk of liver disease and limit disease transmission. Therapeutic vaccine (TV) candidates have been under study for their clinical effects on inducing HBV-specific host immune responses. This review aimed to systematically synthesize updated evidence on the efficacy and safety of TVs in patients with CHB.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This systematic review was performed by searching different databases from January to February 2021. Completed randomized controlled trials that reported TVs' efficacy and\/or safety for treating CHB compared with the standard of care (SOC) or placebo were included. Efficacy and safety estimates were reported as the logarithm of the odds ratio and risk differences, respectively. <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u2005&gt;\u200550% was considered significant heterogeneity. Significant publication bias was considered when Egger\u2019s test <jats:italic toggle=\"yes\">P<\/jats:italic> value\u2005&lt;\u2005.10. The risk of bias was assessed using the Cochrane Risk of Bias tool. The GRADE methodology was used to assess the certainty of the evidence for each outcome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Twenty-four articles with 2889 pooled samples were included. TVs made a significant difference in hepatitis B envelope antigen (HBeAg) SC (log OR\u2005=\u20050.76, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.01) and (log OR\u2005=\u20050.40, <jats:italic toggle=\"yes\">P\u2005<\/jats:italic>=\u2005.03) compared to placebo and combination therapy, respectively. HBeAg SC was significantly affected by TVs at the end of follow up (log OR\u2005=\u20050.49, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.01), with significant HBsAg mean difference (MD\u2005=\u2005\u22120.62, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.00). At the end of treatment, the TVs had no significant effect on HBV DNA negativity over the SOC (log OR\u2005=\u20050.62, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.09) or placebo (log OR\u2005=\u2005\u22120.07, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.91). TVs do not significantly affect the risk of serious adverse events (RD 0.02, 95% CI 0.00\u20130.04).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>In patients with CHB, TVs had significant effects on HBeAg SC compared to the SOC or placebo. There was no significant difference between serious adverse events. TVs are promising treatment strategy to overcome CHB.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000039344","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T18:47:29Z","timestamp":1725043649000},"page":"e39344","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of therapeutic vaccines for the treatment of chronic hepatitis B: A systematic review and meta-analysis of randomized controlled trials update"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5038-700X","authenticated-orcid":false,"given":"Mekuanint","family":"Geta","sequence":"first","affiliation":[{"name":"Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia"},{"name":"Department of Medical Microbiology, School of Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Getachew","family":"Mengistu","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, School of Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia"},{"name":"Department of Laboratory Science, Debre Markos University, Debre Markos, Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Endalew","family":"Yizengaw","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Science, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia"},{"name":"Institute of Biotechnology, Bahir Dar University, Bahir Dar, Ethiopia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsegahun","family":"Manyzewal","sequence":"additional","affiliation":[{"name":"Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asrat","family":"Hailu","sequence":"additional","affiliation":[{"name":"Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimtubeznash","family":"Woldeamanuel","sequence":"additional","affiliation":[{"name":"Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis.","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","article-title":"Global reporting of progress towards elimination of hepatitis B and hepatitis C.","volume":"8","author":"Cui","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.3390\/ijms22115497","article-title":"Immunopathology of chronic hepatitis B infection: role of innate and adaptive immune response in disease progression.","volume":"22","author":"Khanam","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.3389\/fimmu.2019.02240","article-title":"Heterogeneity of HBV-specific CD8+ T-cell failure: implications for immunotherapy.","volume":"10","author":"Heim","year":"2019","journal-title":"Front Immunol"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: from discovery to regulatory approval.","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatology"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00430-014-0373-y","article-title":"Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives.","volume":"204","author":"Gerlich","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"e32894","DOI":"10.1097\/MD.0000000000032894","article-title":"Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B.","volume":"102","author":"Tang","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/rmv.2216","article-title":"Tenofovir disoproxil fumarate for prevention of mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis of randomised control trials.","volume":"31","author":"Zeleke","year":"2021","journal-title":"Rev Med Virol"},{"issue":"Pt 5","key":"R10-20250503","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1099\/jmm.0.063321-0","article-title":"Hepatitis B and hepatitis C virus infections among antiretroviral-naive and -experienced HIV co-infected adults.","volume":"63","author":"Manyazewal","year":"2014","journal-title":"J Med Microbiol"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/cncr.29159","article-title":"Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.","volume":"121","author":"Wang","year":"2015","journal-title":"Cancer"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4049\/jimmunol.0902761","article-title":"CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions.","volume":"184","author":"Phillips","year":"2010","journal-title":"J Immunol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"e1003613","DOI":"10.1371\/journal.ppat.1003613","article-title":"Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes.","volume":"9","author":"Liu","year":"2013","journal-title":"PLoS Pathog"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues.","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"e2511","DOI":"10.1097\/MD.0000000000002511","article-title":"A pilot study of MicroRNAs expression profile in serum and HBsAg particles: predictors of therapeutic vaccine efficacy in chronic hepatitis B patients [published correction appears in Medicine (Baltimore). 2016 May 06;95(18): e16d9].","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jhep.2010.12.031","article-title":"Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges.","volume":"54","author":"Michel","year":"2011","journal-title":"J Hepatol"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1089\/vim.2010.0024","article-title":"The effect of the parenteral route of administration on the immune response to simultaneous nasal and parenteral immunizations using a new HBV therapeutic vaccine candidate.","volume":"23","author":"Lobaina","year":"2010","journal-title":"Viral Immunol"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/emermed-2020-209567","article-title":"Population, Intervention, Comparison, Outcomes and Study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews.","volume":"37","author":"Amir-Behghadami","year":"2020","journal-title":"Emerg Med J"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R22-20250503","first-page":"366","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R23-20250503","first-page":"829","article-title":"Assessment of the strength of recommendation and quality of evidence: GRADE checklist. A descriptive study.","volume":"140","author":"Bezerra","year":"2022","journal-title":"Sao Paulo Medical Journal"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s12072-019-09956-1","article-title":"Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study.","volume":"13","author":"Wu","year":"2019","journal-title":"Hepatol Int"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","article-title":"Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis.","volume":"157","author":"Boni","year":"2019","journal-title":"Gastroenterology"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0201236","article-title":"Treatment of chronic hepatitis B na\u00efve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial).","volume":"13","author":"Mahtab","year":"2018","journal-title":"PLoS One"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3748\/wjg.v23.i2.306","article-title":"Phase IIb trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy.","volume":"23","author":"Yang","year":"2017","journal-title":"World J Gastroenterol"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B.","volume":"65","author":"Lok","year":"2016","journal-title":"J Hepatol"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/gutjnl-2013-305707","article-title":"Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomized trial \u2013 ANRS HB02 VAC-ADN.","volume":"64","author":"Fontaine","year":"2015","journal-title":"Gut"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/liv.12530","article-title":"safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice.","volume":"35","author":"Yoon","year":"2015","journal-title":"Liver Int"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jhep.2013.05.003","article-title":"Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings.","volume":"59","author":"Xu","year":"2013","journal-title":"J Hepatol"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2893.2012.01589.x","article-title":"A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy.","volume":"19","author":"Yang","year":"2012","journal-title":"J Viral Hepat"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"8169","DOI":"10.1016\/j.vaccine.2010.09.093","article-title":"Serum HBeAgsero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine.","volume":"28","author":"Wang","year":"2010","journal-title":"Vaccine"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1128\/AAC.00276-09","article-title":"Randomized controlled study investigating viral suppression and serological response following pre-S1\/pre-S2\/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B.","volume":"53","author":"Le Hoa","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R36-20250503","doi-asserted-by":"crossref","first-page":"e2565","DOI":"10.1371\/journal.pone.0002565","article-title":"A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients.","volume":"3","author":"Xu","year":"2008","journal-title":"PLoS One"},{"key":"R37-20250503","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.1016\/j.vaccine.2007.09.072","article-title":"Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg\/AS02 candidate vaccine and lamivudine.","volume":"25","author":"Vandepapeli\u00e8re","year":"2007","journal-title":"Vaccine"},{"key":"R38-20250503","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.1111\/j.1872-034X.2007.00231.x","article-title":"Use of hepatitis B vaccine for the treatment of chronic hepatitis B.","volume":"37","author":"Ishikawa","year":"2007","journal-title":"Hepatol Res"},{"key":"R39-20250503","first-page":"143","article-title":"Immunomodulation therapy in children with chronic hepatitis B.","volume":"98","author":"Karaoglan","year":"2006","journal-title":"J Natl Med Assoc"},{"key":"R40-20250503","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcv.2004.07.004","article-title":"In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B.","volume":"32","author":"Horiike","year":"2005","journal-title":"J Clin Virol"},{"key":"R41-20250503","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1440-1746.2004.03358.x","article-title":"Efficacy of hepatitis B vaccination and interferon-\u03b1-2b combination therapy versus interferon-\u03b1-2b monotherapy in children with chronic hepatitis B.","volume":"19","author":"Helvaci","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"R42-20250503","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00004836-200310000-00012","article-title":"The lack of effect of therapeutic vaccination with a pre-S2\/S HBV vaccine in the immune tolerant phase of chronic HBV infection.","volume":"37","author":"Yalcin","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"R43-20250503","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s15010-003-3187-1","article-title":"Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial.","volume":"31","author":"Yalcin","year":"2003","journal-title":"Infection"},{"key":"R44-20250503","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/01.inf.0000059443.49414.8b","article-title":"Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection.","volume":"22","author":"Dikici","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"R45-20250503","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1440-1746.2003.02950.x","article-title":"Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection.","volume":"18","author":"Dikici","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"R46-20250503","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/jmv.2165","article-title":"Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin\u20102 in patients with chronic hepatitis B.","volume":"66","author":"Dahmen","year":"2002","journal-title":"J Med Virol"},{"key":"R47-20250503","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1016\/S0264-410X(02)00309-2","article-title":"Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers.","volume":"20","author":"Jung","year":"2002","journal-title":"Vaccine"},{"key":"R48-20250503","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0168-8278(01)00028-9","article-title":"Efficacy and limitations of a specific immunotherapy in chronic hepatitis B.","volume":"34","author":"Pol","year":"2001","journal-title":"J Hepatol"},{"key":"R49-20250503","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study.","volume":"71","author":"Gane","year":"2019","journal-title":"J Hepatol"},{"key":"R50-20250503","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/21645515.2019.1651141","article-title":"Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial.","volume":"16","author":"Zoulim","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"R51-20250503","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3390\/v2061279","article-title":"Antiviral treatment of chronic hepatitis B virus (HBV) infections.","volume":"2","author":"De Clercq","year":"2010","journal-title":"Viruses"},{"key":"R52-20250503","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.apsb.2014.05.002","article-title":"Therapeutic strategies for a functional cure of chronic hepatitis B virus infection.","volume":"4","author":"Chang","year":"2014","journal-title":"Acta Pharm Sin B"},{"issue":"1 Suppl","key":"R53-20250503","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0168-8278(00)80418-3","article-title":"Hepatitis B infection: pathogenesis and management.","volume":"32","author":"Lok","year":"2000","journal-title":"J Hepatol"},{"key":"R54-20250503","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/infdis\/jix025","article-title":"Off-treatment hepatitis B virus (HBV) DNA levels and the prediction of relapse after discontinuation of nucleos(t)ide analogue therapy in patients with chronic hepatitis b: a prospective stop study.","volume":"215","author":"Chang","year":"2017","journal-title":"J Infect Dis"},{"key":"R55-20250503","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.iy.13.040195.000333","article-title":"Hepatitis B virus immunopathogenesis.","volume":"13","author":"Chisari","year":"1995","journal-title":"Annu Rev Immunol"},{"key":"R56-20250503","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1007\/s10620-010-1179-4","article-title":"Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection.","volume":"55","author":"Liaw","year":"2010","journal-title":"Dig Dis Sci"},{"key":"R57-20250503","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12072-009-9140-3","article-title":"HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B.","volume":"3","author":"Liaw","year":"2009","journal-title":"Hepatol Int"},{"key":"R58-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7774\/cevr.2020.9.1.1","article-title":"Hepatitis B vaccination and immunotherapies: an update.","volume":"9","author":"Stasi","year":"2020","journal-title":"Clin Exp Vaccine Res"},{"key":"R59-20250503","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S0140-6736(83)90800-0","article-title":"Intradermal hepatitis B virus vaccine: immunogenicity and side-effects.","volume":"2","author":"Miller","year":"1983","journal-title":"Lancet"},{"key":"R60-20250503","article-title":"Vaccine safety: Hepatitis B Vaccines."}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T23:01:24Z","timestamp":1746313284000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":58,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039344","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2024,8,30]]}}}